ERBB2 and breast cancer: Inhibition of EGFR, Her2 or of their downstream effectors can interrupt the mutp53-HSF1- Her2/EGFR circuitry in cancers bearing Her2/mutp53 double positive mutation (i.e., breast cancer, pancreatic cancer, and non-small cell lung cancers) [11].